{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Complete response rate will be evaluated over all courses of study treatment. The proportion of CR/CRi responses will be estimated by the number of CR/CRi responses divided by the total number of evaluable patients.","groups":[{"description":"Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.","id":"OG000","title":"Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)"}],"paramType":"NUMBER","populationDescription":"Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Complete Response Rate (CR or CRi) Per the National Comprehensive Cancer Network (NCCN) Guidelines or According to Specific Criteria From Expert Panels","type":"PRIMARY","unitOfMeasure":"percentage of patients"}